- The weight loss drug market is dominated by major players like Pfizer, Viking Therapeutics, Eli Lilly, and Novo Nordisk, with potential M&A activity and public commentary.
- Eli Lilly and Novo Nordisk faced legal actions and partnership terminations regarding compliance and customer deception.
Lilly and Novo Nordisk filed lawsuits alleging compounded drugs infringe on trademarks and challenging federal guidelines.
1 report, 1 independent
Updated Sep 4
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Lilly and Novo Nordisk filed lawsuits alleging compounded drugs infringe on trademarks and challenging federal guidelines.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Eli Lilly and Company
American pharmaceutical company
-
Novo Nordisk
Danish pharmaceutical company
Related events
- Eli Lilly and Company plans to submit a drug candidate to the FDA for review and approval.
- Eli Lilly and Novo Nordisk are competing for market share in the weight loss drug sector.
- Eli Lilly and Company received full FDA approval, expanded a safety study into India, and broke ground on a new facility in Houston while competing in the GLP-1 market.
- Health Canada regulates the approval of generic pharmaceuticals, allowing market entry following patent expiration.
Coverage
Newest first; wire copies grouped- Investing.comHims & Hers gains after court rejects Eli Lilly’s case against Willow Investing.com -- Shares of Hims Hers Health Inc (NYSE:HIMS) jumped 8.2% Wednesday after a key legal development eased market conc